Aplastic Anemia Overview
Pathophysiology
Aplastic anemia is fundamentally an immune-mediated bone marrow failure syndrome where oligoclonally expanded cytotoxic T cells attack and destroy hematopoietic stem cells, resulting in pancytopenia and bone marrow hypocellularity 1, 2.
The autoimmune mechanism involves:
- Type 1 cytotoxic T lymphocytes that induce apoptosis of hematopoietic progenitors through dysregulated immune responses
- Upregulation of T-bet, a transcription factor binding to the interferon-gamma promoter region in T cells
- Significant reduction in regulatory T cells in peripheral blood, which normally suppress autoimmune responses 2
- Recent evidence shows somatic mutations in MDS/AML candidate genes occur in approximately one-third of AA patients 3
- Telomerase complex gene mutations (loss-of-function) may underlie disease development in a minority of cases 2
While toxic exposures (benzene), medications (chloramphenicol, antiepileptics), and infections are associated with some cases, most acquired AA cases have no identifiable inciting event 1.
Diagnostic Criteria
Severe AA (SAA) is defined by bone marrow cellularity <25% (or 25-50% with <30% residual hematopoietic cells), plus at least 2 of the following:
- Neutrophils <0.5 × 10⁹/L
- Platelets <20 × 10⁹/L
- Reticulocytes <60 × 10⁹/L 1
Very severe AA meets the same criteria except neutrophils are <0.2 × 10⁹/L 1.
Critical caveat: AA is a diagnosis of exclusion—you must rule out inherited bone marrow failure syndromes, myelodysplastic syndromes, and paroxysmal nocturnal hemoglobinuria through comprehensive genetic diagnostics, family history, and flow cytometry 1.
Treatment Algorithm
First-Line Treatment Selection
For younger patients (<40 years) with an HLA-matched sibling donor: proceed directly to allogeneic hematopoietic stem cell transplantation (allo-HSCT) 4. This is the most definitive recommendation from the 2026 ASH guidelines.
For younger patients without a matched sibling donor OR older adults: initiate immunosuppressive therapy (IST) with horse antithymocyte globulin (ATG) + cyclosporine + eltrombopag 4, 1. The 2026 ASH guidelines specifically recommend adding eltrombopag as soon as possible after ATG administration, as this combination achieves approximately 80% initial response rates 1.
Emerging paradigm shift: The 2026 ASH guidelines now recommend considering allo-HSCT from HLA-matched unrelated donors as first-line therapy for younger patients, given improving outcomes with alternative donors 4. This represents a significant evolution from older guidelines that reserved unrelated donor transplants for second-line therapy.
Specific IST Regimen Details
The standard IST consists of:
- Horse ATG (preferred over rabbit ATG based on superior outcomes)
- Cyclosporine
- Eltrombopag (TPO-RA) started immediately after ATG 4, 5
Second-Line Treatment
For patients who fail first-line IST:
- Allo-HSCT from matched unrelated or haploidentical donors is now recommended as second-line therapy 4
- Alternative: Second course of IST with or without TPO-RAs 1
Supportive Care
The 2026 ASH guidelines strongly recommend:
- Antibiotic prophylaxis for patients with neutropenia
- Antifungal prophylaxis for high-risk patients 4
Pharmacokinetics of Key Therapies
While the guidelines don't extensively detail pharmacokinetics, the critical therapeutic agents are:
Eltrombopag (TPO-RA): Approved in 2014 for relapsed/refractory SAA and in 2018 for treatment-naïve SAA in combination with IST. It stimulates thrombopoietin receptors to promote hematopoietic stem cell proliferation 1.
Cyclosporine: Calcineurin inhibitor that suppresses T-cell activation and cytokine production, directly targeting the autoimmune mechanism 1, 6.
ATG: Polyclonal antibody preparation that depletes T lymphocytes, eliminating the cytotoxic cells attacking hematopoietic stem cells 6.
Mortality and Prognosis
Without treatment, patients with SAA face high mortality risk from infection or hemorrhage 1. However, modern therapy has dramatically transformed outcomes:
With allo-HSCT from matched sibling donors: High cure rates with many patients living decades without disease recurrence or clonal disorders 7. Recent data show improved outcomes even with unrelated and haploidentical donors 4.
With IST + eltrombopag: Approximately 80% initial response rate 1. However, critical long-term risks include:
- Disease relapse
- Secondary myelodysplastic syndrome (MDS)
- Acute myeloid leukemia (AML) development 7
Long-term survival has significantly improved even among IST nonresponders due to advances in supportive care and better salvage treatments 2. The incidence remains rare at approximately 2 cases per million annually, with peak occurrence at ages 15-25 and over 60 1, 8.
The fundamental mortality/morbidity trade-off: Allo-HSCT offers definitive cure with lower long-term clonal evolution risk but carries upfront transplant-related mortality and GVHD risks. IST offers lower immediate risk but persistent long-term risks of relapse and malignant transformation, making allo-HSCT increasingly favored as first-line therapy when suitable donors are available 7.